Parnax Lab profitability ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Mar 2025FY24Mar 2024FY23Mar 2023FY22Mar 2022FY21 and earlierAlpha Plus
Margins
FY21 and earlierEvery year the company has filed comes with Alpha Plus.
17.6%28.4%21.1%19.1%
16.7%27.6%20.1%18.5%
208.9%−1,639.9%56.0%—
26.5%32.9%21.8%10.9%
4.0%−0.5%−4.5%−5.0%
Additional
24.9%25.5%26.0%30.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PARNAXLAB₹109.47

Parnax Lab Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Margins
EBITDA Margin19.1421.0528.3717.61
Operating Margin18.5120.1427.5916.70
Incremental Operating Margin—56.03-1,639.85208.90
Pretax Margin10.9121.7732.8926.47
FCF Margin-5.04-4.46-0.503.98
Additional
Effective Tax Rate30.5625.9625.4824.94
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.